当前位置: X-MOL 学术Cancer Cell › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Venetoclax in Lymphoid Malignancies: New Insights, More to Learn.
Cancer Cell ( IF 48.8 ) Pub Date : 2019-10-14 , DOI: 10.1016/j.ccell.2019.09.008
Rachel Thijssen 1 , Andrew W Roberts 2
Affiliation  

In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.

中文翻译:

Venetoclax在淋巴恶性肿瘤中的应用:新见解,更多知识。

在本期《癌细胞》中,Guieza等人。他说,在慢性淋巴细胞性白血病患者中,生存蛋白MCL1的过表达和细胞能量代谢的重新编程可导致对BCL2抑制剂venetoclax的耐药性。这为了解继发性委内瑞拉抗药性增加了一个新的维度。
更新日期:2019-11-09
down
wechat
bug